JPH0577657B2 - - Google Patents
Info
- Publication number
- JPH0577657B2 JPH0577657B2 JP59045764A JP4576484A JPH0577657B2 JP H0577657 B2 JPH0577657 B2 JP H0577657B2 JP 59045764 A JP59045764 A JP 59045764A JP 4576484 A JP4576484 A JP 4576484A JP H0577657 B2 JPH0577657 B2 JP H0577657B2
- Authority
- JP
- Japan
- Prior art keywords
- detoxified
- polysaccharide
- gram
- protein
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000004676 glycans Chemical class 0.000 claims abstract description 63
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 63
- 239000005017 polysaccharide Substances 0.000 claims abstract description 63
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 53
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 53
- 239000002158 endotoxin Substances 0.000 claims abstract description 44
- 239000000203 mixture Substances 0.000 claims abstract description 43
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 36
- 241000894006 Bacteria Species 0.000 claims abstract description 31
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims abstract description 20
- 125000003172 aldehyde group Chemical group 0.000 claims abstract description 11
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 19
- 150000002632 lipids Chemical class 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 230000001900 immune effect Effects 0.000 claims description 9
- 231100000252 nontoxic Toxicity 0.000 claims description 6
- 230000003000 nontoxic effect Effects 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 231100000419 toxicity Toxicity 0.000 claims description 5
- 230000001988 toxicity Effects 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 108700012359 toxins Proteins 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims 1
- 238000009877 rendering Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 229940124452 immunizing agent Drugs 0.000 abstract description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 108010045362 Serum Globulins Proteins 0.000 description 9
- 102000005686 Serum Globulins Human genes 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 5
- -1 haloacyl halide Chemical class 0.000 description 5
- 230000000521 hyperimmunizing effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010077805 Bacterial Proteins Proteins 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 208000032536 Pseudomonas Infections Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 238000009739 binding Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241001529572 Chaceon affinis Species 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 210000004423 amoeboid cell Anatomy 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 230000007893 endotoxin activity Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 108010074605 gamma-Globulins Proteins 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- KSSNXJHPEFVKHY-UHFFFAOYSA-N phenol;hydrate Chemical compound O.OC1=CC=CC=C1 KSSNXJHPEFVKHY-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000872931 Myoporum sandwicense Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000772415 Neovison vison Species 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940001442 combination vaccine Drugs 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000588754 Klebsiella sp. Species 0.000 description 1
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical group O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000334216 Proteus sp. Species 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GHWVXCQZPNWFRO-UHFFFAOYSA-N butane-2,3-diamine Chemical compound CC(N)C(C)N GHWVXCQZPNWFRO-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000013627 low molecular weight specie Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-M periodate Chemical compound [O-]I(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-M 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/802—Antibody or antigen-binding fragment thereof that binds gram-positive bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/475,415 US4663160A (en) | 1983-03-14 | 1983-03-14 | Vaccines for gram-negative bacteria |
| US475415 | 1983-03-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59175440A JPS59175440A (ja) | 1984-10-04 |
| JPH0577657B2 true JPH0577657B2 (OSRAM) | 1993-10-27 |
Family
ID=23887470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59045764A Granted JPS59175440A (ja) | 1983-03-14 | 1984-03-12 | グラム陰性バクテリアのワクチン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4663160A (OSRAM) |
| EP (2) | EP0118831B1 (OSRAM) |
| JP (1) | JPS59175440A (OSRAM) |
| AT (1) | ATE44238T1 (OSRAM) |
| DE (1) | DE3478789D1 (OSRAM) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8833987B2 (en) | 2005-09-14 | 2014-09-16 | Donnelly Corporation | Mirror reflective element sub-assembly for exterior rearview mirror of a vehicle |
| US8884788B2 (en) | 1998-04-08 | 2014-11-11 | Donnelly Corporation | Automotive communication system |
| US8908039B2 (en) | 2000-03-02 | 2014-12-09 | Donnelly Corporation | Vehicular video mirror system |
| US8908040B2 (en) | 2007-10-04 | 2014-12-09 | Magna Electronics Inc. | Imaging system for vehicle |
| US9014966B2 (en) | 2000-03-02 | 2015-04-21 | Magna Electronics Inc. | Driver assist system for vehicle |
| US9019091B2 (en) | 1999-11-24 | 2015-04-28 | Donnelly Corporation | Interior rearview mirror system |
| US9018577B2 (en) | 2007-08-17 | 2015-04-28 | Magna Electronics Inc. | Vehicular imaging system with camera misalignment correction and capturing image data at different resolution levels dependent on distance to object in field of view |
| US9073491B2 (en) | 2002-09-20 | 2015-07-07 | Donnelly Corporation | Exterior rearview mirror assembly |
| US9090211B2 (en) | 2002-09-20 | 2015-07-28 | Donnelly Corporation | Variable reflectance mirror reflective element for exterior mirror assembly |
| US9278654B2 (en) | 1999-11-24 | 2016-03-08 | Donnelly Corporation | Interior rearview mirror system for vehicle |
| US9352623B2 (en) | 2001-01-23 | 2016-05-31 | Magna Electronics Inc. | Trailer hitching aid system for vehicle |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5360897A (en) * | 1981-08-31 | 1994-11-01 | The University Of Rochester | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad |
| EP0215131B1 (en) * | 1985-03-11 | 1992-06-17 | Teijin Limited | E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma |
| IT1187753B (it) * | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| DK163176C (da) * | 1985-09-27 | 1992-06-22 | Schweiz Serum & Impfinst | Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen |
| US4755381A (en) * | 1986-03-27 | 1988-07-05 | Swiss Serum And Vaccine Institute Berne | Klebsiella capsular polysaccharide vaccine |
| US4789544A (en) * | 1986-05-23 | 1988-12-06 | Midcon Labs. Inc. | Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation |
| DE3727987A1 (de) * | 1987-08-21 | 1989-03-02 | Sleytr Uwe B | Pharmazeutische struktur |
| US5043158A (en) * | 1987-08-21 | 1991-08-27 | Chembiomed, Ltd. | Immunogenic compositions containing ordered carriers |
| US5063054A (en) * | 1988-04-18 | 1991-11-05 | Joseph Chang | Microbial products used for treatment of hepatitis |
| NZ239643A (en) * | 1990-09-17 | 1996-05-28 | North American Vaccine Inc | Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group. |
| US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| FR2682388B1 (fr) * | 1991-10-10 | 1995-06-09 | Pasteur Merieux Serums Vacc | Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal. |
| AU678549B2 (en) * | 1992-01-16 | 1997-06-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Detoxified LPS-cholera toxin conjugate vaccine for prevention of cholera |
| US5554730A (en) * | 1993-03-09 | 1996-09-10 | Middlesex Sciences, Inc. | Method and kit for making a polysaccharide-protein conjugate |
| US5695768A (en) | 1995-06-07 | 1997-12-09 | Alberta Research Council | Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides |
| US5866132A (en) * | 1995-06-07 | 1999-02-02 | Alberta Research Council | Immunogenic oligosaccharide compositions |
| CA2333931C (en) | 1998-07-15 | 2013-09-03 | Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
| CN1263510C (zh) * | 1998-08-19 | 2006-07-12 | 巴克斯特健康护理股份有限公司 | 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用 |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| WO2003094961A1 (en) * | 2002-05-09 | 2003-11-20 | Massimo Porro | Improved polysaccharide and glycoconjugate vaccines_____________ |
| US8663656B2 (en) | 2002-10-11 | 2014-03-04 | Novartis Ag | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| CA3042073C (en) | 2003-01-30 | 2022-09-13 | Novartis Vaccines And Diagnostics S.R.L. | Injectable vaccines against multiple meningococcal serogroups |
| SI1670506T1 (sl) | 2003-10-02 | 2013-03-29 | Novartis Ag | Tekoča cepiva proti multiplim meningokoknim seroskupinam |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| WO2005044861A1 (en) * | 2003-10-31 | 2005-05-19 | Wyeth Holdings Corporation | Polysaccharides of helicobacter pylori |
| EP1713508A2 (en) * | 2004-01-29 | 2006-10-25 | Biosynexus Incorporated | Use of amino-oxy functional groups in the preparation of vaccine conjugates |
| GB0406013D0 (en) | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference |
| GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| EP2272531A3 (en) | 2004-04-30 | 2011-04-13 | Novartis Vaccines and Diagnostics S.r.l. | Integration of meningococcal conjugate vaccination |
| GB0411387D0 (en) | 2004-05-21 | 2004-06-23 | Chiron Srl | Analysis of saccharide length |
| US8246993B2 (en) * | 2004-06-10 | 2012-08-21 | Cytogel Pharma, Llc | Advantageous hydrogel composition |
| GB0413868D0 (en) | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
| US20060013886A1 (en) * | 2004-06-28 | 2006-01-19 | Daqing Wu | Injectable microspheres |
| CA2581330A1 (en) | 2004-09-21 | 2006-03-30 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to mannuronic acid specific binding peptides |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| GB0605757D0 (en) | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components |
| ES2383209T3 (es) | 2006-03-22 | 2012-06-19 | Novartis Ag | Regímenes para la inmunización con conjugados meningococicos |
| GB0612854D0 (en) | 2006-06-28 | 2006-08-09 | Novartis Ag | Saccharide analysis |
| HRP20120557T1 (hr) | 2006-09-07 | 2012-07-31 | GlaxoSmithKline@Biologicals@s@a | Kombinirano cjepivo sa smanjenim količinama antigena poliovirusa |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| UY31064A1 (es) | 2007-05-02 | 2009-01-05 | Glaxosmithkline Biolog Sa | Vacuna |
| GB0713880D0 (en) * | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| DK2200642T3 (da) | 2007-10-19 | 2012-07-16 | Novartis Ag | Meningococvaccinepræparater |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| AU2009215364B2 (en) | 2008-02-21 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Meningococcal fHBP polypeptides |
| WO2010049806A1 (en) | 2008-10-27 | 2010-05-06 | Novartis Ag | Purification method |
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| CA2747340A1 (en) | 2008-12-17 | 2010-06-24 | Novartis Ag | Meningococcal vaccines including hemoglobin receptor |
| WO2010109323A1 (en) | 2009-03-24 | 2010-09-30 | Novartis Ag | Adjuvanting meningococcal factor h binding protein |
| JP5668049B2 (ja) | 2009-03-24 | 2015-02-12 | ノバルティス アーゲー | 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ |
| US8679505B2 (en) | 2009-04-14 | 2014-03-25 | Novartis Ag | Compositions for immunising against Staphylococcus aureus |
| WO2011017101A2 (en) | 2009-07-27 | 2011-02-10 | Fina Biosolutions, Llc | Method for producing protein-carbohydrate vaccines reduced in free carbohydrate |
| US20110076300A1 (en) | 2009-08-27 | 2011-03-31 | Mariagrazia Pizza | Hybrid Polypeptides Including Meningococcal fHBP Sequences |
| CA2773637A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Combination vaccines against respiratory tract diseases |
| AU2010352695B2 (en) | 2009-09-30 | 2014-08-21 | Glaxosmithkline Biologicals S.A. | Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides |
| US20130022639A1 (en) | 2009-09-30 | 2013-01-24 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
| AU2010310985B2 (en) | 2009-10-27 | 2014-11-06 | Glaxosmithkline Biologicals S.A. | Modified meningococcal fHBP polypeptides |
| BR122019005883A8 (pt) * | 2009-10-30 | 2022-10-04 | Novartis Ag | Método para liberação de polissacarídeo capsular, processo de purificação de sacarídeos capsulares tipo 5 e tipo 8 de staphylococcus aureus e composição |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| SG10201506160VA (en) | 2009-12-17 | 2015-09-29 | Fina Biosolutions Llc | Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines |
| JP5781542B2 (ja) | 2009-12-30 | 2015-09-24 | ノバルティス アーゲー | Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原 |
| GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| CA2797892C (en) | 2010-05-21 | 2019-10-15 | Cytogel Pharma, Llc | Materials and methods for treatment of inflammation |
| AU2011268507B2 (en) | 2010-06-25 | 2014-08-14 | Novartis Ag | Combinations of meningococcal factor H binding proteins |
| WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
| WO2012085668A2 (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
| US20140112950A1 (en) | 2011-03-02 | 2014-04-24 | Manmohan Singh | Combination vaccines with lower doses of antigen and/or adjuvant |
| GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
| JP6170932B2 (ja) | 2011-11-07 | 2017-07-26 | ノバルティス アーゲー | ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子 |
| DE202012012768U1 (de) | 2011-12-06 | 2014-01-21 | Valneva Austria Gmbh | Aluminium-Verbindungen zur Verwendung in Therapeutika und Impfstoffen |
| GB201121301D0 (en) | 2011-12-12 | 2012-01-25 | Novartis Ag | Method |
| US10596246B2 (en) | 2011-12-29 | 2020-03-24 | Glaxosmithkline Biological Sa | Adjuvanted combinations of meningococcal factor H binding proteins |
| US20150132339A1 (en) | 2012-03-07 | 2015-05-14 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
| WO2013132043A1 (en) | 2012-03-08 | 2013-09-12 | Novartis Ag | Combination vaccines with tlr4 agonists |
| JP2015522692A (ja) | 2012-07-16 | 2015-08-06 | ファイザー・インク | 糖およびその使用 |
| BR112015005056A2 (pt) | 2012-09-06 | 2017-11-21 | Novartis Ag | vacinas de combinação com sorogrupo b meningococcus e d/t/p |
| EP2903650B1 (en) | 2012-10-02 | 2018-04-04 | GlaxoSmithKline Biologicals SA | Nonlinear saccharide conjugates |
| BR112015008040A2 (pt) | 2012-10-12 | 2017-07-04 | Glaxosmithkline Biologicals Sa | composição de vacina, vacina de combinação, e, processos para preparar um componente ap e para a fabricação de uma composição de vacina |
| CA2892688A1 (en) | 2012-11-30 | 2014-06-05 | Glaxosmithkline Biologicals Sa | Pseudomonas antigens and antigen combinations |
| EP2950819B1 (en) | 2013-02-01 | 2018-03-28 | GlaxoSmithKline Biologicals SA | Intradermal delivery of immunological compositions comprising toll-like receptor agonists |
| HK1225739A1 (zh) * | 2013-12-03 | 2017-09-15 | Virometix Ag | 针对肺炎链球菌进行保护的富含脯氨酸的肽 |
| EA034954B1 (ru) | 2014-02-28 | 2020-04-10 | Глаксосмитклайн Байолоджикалс Са | МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp |
| EP3034516A1 (en) | 2014-12-19 | 2016-06-22 | Novartis AG | Purification of streptococcal capsular polysaccharide |
| WO2018042017A2 (en) | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae |
| EP3551668A1 (en) | 2016-12-06 | 2019-10-16 | GlaxoSmithKline Biologicals S.A. | Purification process for capsular polysaccharide |
| MX2019015524A (es) | 2017-06-23 | 2020-09-10 | Univ Maryland | Composiciones inmunogenicas. |
| US10975121B2 (en) | 2017-06-24 | 2021-04-13 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
| EP3607967A1 (en) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
| EP3799884A1 (en) | 2019-10-01 | 2021-04-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
| GB202013262D0 (en) | 2020-08-25 | 2020-10-07 | Glaxosmithkline Biologicals Sa | Vaccine Composition |
| GB202208089D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| GB202208093D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH396316A (de) * | 1960-07-12 | 1965-07-31 | Wander Ag Dr A | Verfahren zur Herstellung von Impfstoffen |
| US3987164A (en) * | 1970-10-20 | 1976-10-19 | Yuzuru Homma | Method for prevention of pseudomonas aeruginosa infections |
| US4185090A (en) * | 1972-02-02 | 1980-01-22 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| NL7506560A (nl) * | 1974-06-04 | 1975-12-08 | Wellcome Found | Werkwijze voor het bereiden van geconjugeerde pros- taglandinen. |
| JPS51106714A (OSRAM) * | 1975-03-12 | 1976-09-21 | Tokyo Daigaku | |
| JPS5296729A (en) * | 1976-02-05 | 1977-08-13 | Shionogi & Co Ltd | Mixed vaccin for cyanomycosis |
| FR2460139A1 (fr) * | 1979-06-29 | 1981-01-23 | Pasteur Institut | Fraction antigenique glycopeptidique vaccinante a tres grande immunogenicite isolee de cultures de germes pathogenes, procedes d'isolement de cette fraction et vaccins contenant ladite fraction |
| JPS5639022A (en) * | 1979-09-05 | 1981-04-14 | Hayashibara Biochem Lab Inc | Preparation of vaccine |
| US4285936A (en) * | 1979-12-10 | 1981-08-25 | The United States Of America As Represented By The Secretary Of The Army | Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa |
| US4356170A (en) * | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4459286A (en) * | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
-
1983
- 1983-03-14 US US06/475,415 patent/US4663160A/en not_active Expired - Fee Related
-
1984
- 1984-02-29 AT AT84102119T patent/ATE44238T1/de not_active IP Right Cessation
- 1984-02-29 DE DE8484102119T patent/DE3478789D1/de not_active Expired
- 1984-02-29 EP EP84102119A patent/EP0118831B1/en not_active Expired
- 1984-02-29 EP EP88105929A patent/EP0306607A1/en not_active Withdrawn
- 1984-03-12 JP JP59045764A patent/JPS59175440A/ja active Granted
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8884788B2 (en) | 1998-04-08 | 2014-11-11 | Donnelly Corporation | Automotive communication system |
| US9481306B2 (en) | 1998-04-08 | 2016-11-01 | Donnelly Corporation | Automotive communication system |
| US9221399B2 (en) | 1998-04-08 | 2015-12-29 | Magna Mirrors Of America, Inc. | Automotive communication system |
| US9019091B2 (en) | 1999-11-24 | 2015-04-28 | Donnelly Corporation | Interior rearview mirror system |
| US9278654B2 (en) | 1999-11-24 | 2016-03-08 | Donnelly Corporation | Interior rearview mirror system for vehicle |
| US9315151B2 (en) | 2000-03-02 | 2016-04-19 | Magna Electronics Inc. | Driver assist system for vehicle |
| US9014966B2 (en) | 2000-03-02 | 2015-04-21 | Magna Electronics Inc. | Driver assist system for vehicle |
| US8908039B2 (en) | 2000-03-02 | 2014-12-09 | Donnelly Corporation | Vehicular video mirror system |
| US9352623B2 (en) | 2001-01-23 | 2016-05-31 | Magna Electronics Inc. | Trailer hitching aid system for vehicle |
| US10272839B2 (en) | 2001-01-23 | 2019-04-30 | Magna Electronics Inc. | Rear seat occupant monitoring system for vehicle |
| US9073491B2 (en) | 2002-09-20 | 2015-07-07 | Donnelly Corporation | Exterior rearview mirror assembly |
| US9090211B2 (en) | 2002-09-20 | 2015-07-28 | Donnelly Corporation | Variable reflectance mirror reflective element for exterior mirror assembly |
| US9341914B2 (en) | 2002-09-20 | 2016-05-17 | Donnelly Corporation | Variable reflectance mirror reflective element for exterior mirror assembly |
| US9545883B2 (en) | 2002-09-20 | 2017-01-17 | Donnelly Corporation | Exterior rearview mirror assembly |
| US9045091B2 (en) | 2005-09-14 | 2015-06-02 | Donnelly Corporation | Mirror reflective element sub-assembly for exterior rearview mirror of a vehicle |
| US8833987B2 (en) | 2005-09-14 | 2014-09-16 | Donnelly Corporation | Mirror reflective element sub-assembly for exterior rearview mirror of a vehicle |
| US9018577B2 (en) | 2007-08-17 | 2015-04-28 | Magna Electronics Inc. | Vehicular imaging system with camera misalignment correction and capturing image data at different resolution levels dependent on distance to object in field of view |
| US8908040B2 (en) | 2007-10-04 | 2014-12-09 | Magna Electronics Inc. | Imaging system for vehicle |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0118831B1 (en) | 1989-06-28 |
| DE3478789D1 (en) | 1989-08-03 |
| EP0118831A2 (en) | 1984-09-19 |
| EP0118831A3 (en) | 1986-12-10 |
| EP0306607A1 (en) | 1989-03-15 |
| US4663160A (en) | 1987-05-05 |
| ATE44238T1 (de) | 1989-07-15 |
| JPS59175440A (ja) | 1984-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0577657B2 (OSRAM) | ||
| US4036953A (en) | Process for preparing vaccine adjuvant | |
| US5773007A (en) | Vaccine compositions | |
| JP3927233B2 (ja) | 肺炎双球菌感染症に対する免疫化のための肺炎双球菌多糖−組み換えニューモリシン結合体ワクチン類 | |
| US4460575A (en) | Vaccinal complex containing a specific antigen and vaccine containing it | |
| US4271147A (en) | Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same | |
| US4693891A (en) | Vaccine for Pseudomonas aeruginosa | |
| JP5914344B2 (ja) | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ５型および８型の莢膜糖の精製 | |
| US4285936A (en) | Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa | |
| JP2911603B2 (ja) | 新規な弱毒化シュードモナス・エルギノーザ株 | |
| Fiske et al. | Method for reducing endotoxin in Moraxella catarrhalis UspA2 protein preparations | |
| US3976544A (en) | Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction | |
| EP0407037B1 (en) | Process for removing bacterial endotoxin from gram-negative polysaccharides | |
| CA2406229C (en) | Anti-sepsis conjugate vaccine | |
| US4152423A (en) | Immunological agents | |
| Byrd et al. | Preparation, characterization, and immunogenicity of conjugate vaccines directed against Actinobacillus pleuropneumoniae virulence determinants | |
| JPS58126797A (ja) | ジサツカライドトリペプチド及びジサツカライドテトラペプチドの製法 | |
| Dinarello et al. | Exogenous pyrogens | |
| AU678549B2 (en) | Detoxified LPS-cholera toxin conjugate vaccine for prevention of cholera | |
| HELTING et al. | SEROTYPE DETERMINANT PROTEIN OF NEISSERIA MENINGITIDIS: Large Scale Preparation by Direct Detergent Treatment of the Bacterial Cells | |
| Muniandy et al. | Immunogenicity of purified lipopolysaccharide or protein–oligosaccharide conjugates of Pasteurella multocida type 6: B in mice | |
| JP7311103B2 (ja) | ワクチン | |
| RU2412197C2 (ru) | Полимерный фрагмент пептидогликана клеточной стенки грамотрицательных бактерий, способ его получения и его применение в качестве иммуностимулятора | |
| RU2407792C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ IgAl-ПРОТЕАЗЫ ИЗ КУЛЬТУРЫ NEISSERIA MENINGITIDIS СЕРОГРУППЫ А И ИММУНОГЕННЫЙ ПРЕПАРАТ НА ЕЕ ОСНОВЕ | |
| Getnick | Studies on the antigenicity of streptolysin |